The Screening and Evaluation of Experimental Antiparasitic Drugs.
Annual rept. no. 14, 1 Oct 81-5 May 82,
MIAMI UNIV FLA LEO RANE RESEARCH LAB
Pagination or Media Count:
The investigation included three antimalarial screens, two African trypanosome screens, and an American trypanosome screen. Three antimalarial screens were a primary blood schizonticidal test using Plasmodium berghei, a primary causal prophylactic test using Plasmodium voelii and Anopheles stephensi mosquitoes, and a secondary drug screening system using both of the above species of rodent malaria. The two African trypanosome systems included a primary screen and a secondary drug-resistant screen. The American trypanosome system was a primary one. In the primary antimalarial blood schizonticidal test 1, 425 dose-level tests were done with 320 exhibiting activity. In the prophylactic antimalarial test 756 three dose-level tests were performed to detect activity against sporozoites andor exoerythrocytic stages. 80 compounds were active. In the regular secondary 8 compounds were tested against the drug-sensitive P-line of P. berghei, while 12 compounds were tested against the drug mefloquine resistant-line. Other special tests included, 1 Determining how stable the drug-resistant lines would be when drug pressure is removed, 2 How stable drug resistance is when drug-resistant parasites are mixed with drug-sensitive parasites, 3 The development of mefloquine and Fansidar resistance when mixed together, 4 The activity of silver sulfonamide and its non-silver analog against malaria and African and American trypanosomes, 5 Testing a new prophylactic antimalarial test system using exoerythrocytic schizonts transfered from rat liver to mouse peritoneal activity.